JFG
CERE

Jefferies Financial Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Jefferies Financial Group’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-25,000
Closed -$795K – 2073
2023
Q2 		$795K Buy
25,000
+24,980
+124,900% +$767K 0.01% 1014
2023
Q1 		$488 Sell
20
-3,098
-99% -$90.9K ﹤0.01% 1585
2022
Q4 		$98.3K Buy
+3,118
New +$88K ﹤0.01% 1369

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jefferies Financial Group's CERE Position: Q3 2023 in Review

Jefferies Financial Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2023, closing a stake of 25,000 shares — an estimated $795K sold.

Jefferies Financial Group first reported a position in CERE in Q4 2022 and held it in 3 quarters. The position peaked at $795K in Q2 2023. 119 funds tracked by Wall St. Rank hold CERE as of Q3 2023.

  • Jefferies Financial Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Jefferies Financial Group sold 25,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2023, an estimated $795K.
  • Jefferies Financial Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
  • Jefferies Financial Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $795K in Q2 2023.
  • 119 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2023.

Based on Jefferies Financial Group's 13F filing for Q3 2023, filed 14 Nov 2023.